Assessing adolescent preference in the treatment of first-episode psychosis and psychosis risk

Early Intervention in Psychiatry

Volumn 8, Issue 3, 2014, Pages 281-285

  Welsh, Patrick ^a,b   Tiffin, Paul A ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

^b The Royal College of Psychiatrists   (United Kingdom)

Author keywords

Intervention; Psychosis; Risk; Youth

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ART THERAPY; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; COGNITIVE THERAPY; EARLY INTERVENTION; FAMILY THERAPY; HUMAN; MEDICAL INFORMATION; MENTAL HEALTH; NATIONAL HEALTH SERVICE; PATIENT PREFERENCE; PEER GROUP; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; QUESTIONNAIRE; UNITED KINGDOM; WATCHFUL WAITING; ADOLESCENT BEHAVIOR; CHILD; DISEASE PREDISPOSITION; FEMALE; MALE; PROCEDURES; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SELF REPORT;

ADOLESCENT; ADOLESCENT BEHAVIOR; CHILD; DISEASE SUSCEPTIBILITY; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; PATIENT PREFERENCE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISK ASSESSMENT; SELF REPORT;

EID: 84904757908     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12077     Document Type: Article

References (28)

1. Frazier JA, McClellan J, Findling RL etal. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007; 46: 979-988.
2. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H. Long-term course of adolescent schizophrenia. Schizophr Bull 2005; 31: 769-780.
3. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303.
4. Meyer SE, Bearden CE, Lux S etal. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol 2005; 15: 434-451.
5. Morrison AP, Stewart SL, French P etal. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Interv Psychiatry 2011; 5: 24-32.
6. NICE. Psychosis and schizophrenia in children and young people: recognition and management. CG155. London: National Institute for Health and Clinical Excellence, 2013.
7. Fraguas D, Merchán-Naranjo J, Laita P etal. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008; 69: 1165-1175.
8. Schizophrenia Commission. The abandoned illness: a report from the Schizophrenia Commission. London: Rethink Mental Illness; 2012. [Cited 10 July 2013.] Available from URL: http://www.schizophreniacommission.org.uk/
9. Adams JR, Drake RE. Shared decision-making and evidence-based practice. Community Ment Health J 2006; 42: 87-105.
10. Black N, Jenkinson C. How can patients' views of their care enhance quality improvement? BMJ 2009; 339: 202-205.
11. Staley K. Exploring Impact: Public Involvement in NHS, Public Health and Social Care Research. Eastleigh: INVOLVE, 2009.
12. O'Brien MS, Crickard L, Rapp C etal. Critical issues for psychiatric medication shared decision making with youth and families. Fam Soc 2011; 93: 310-316.
13. Day JC, Bentall RP, Roberts C etal. Attitudes toward antipsychotic medication:the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717-724.
14. Grealish A, Tai S, Hunter A, Morrison AP. Qualitative exploration of empowerment from the perspective of young people with psychosis. Clin Psychol Psychother 2013; 20: 136-148.
15. Byrne R, Davies L, Morrison AP. Priorities and preferences for the outcomes of treatment of psychosis: a service user perspective. Psychosis 2010; 2: 210-217.
16. Schimmelmann B, Schultze-Lutter F. Early detection and intervention of psychosis in children and adolescents: urgent need for studies. Eur Child Adolesc Psychiatry 2012; 21: 239-241.
17. Booth T, Booth W. Sounds of silence: narrative research with inarticulate subjects. Disabil Soc 1996; 11: 55-69.
18. Brummitt K, Addington J. Treatment possibilities for individuals at clinical high risk of psychosis. Early Interv Psychiatry 2013; 7: 155-161.
19. Welsh P, Tiffin PA. Observations of a small sample of adolescents experiencing an at-risk mental state (ARMS) for psychosis. Schizophr Bull 2012; 38: 215-218.
20. Welsh P, Mediavilla JL, Tiffin PA. Attitudes and knowledge of child and adolescent mental health clinicians in relation to the psychosis risk syndrome. Early Interv Psychiatry 2011; 5: 355-359.
21. Welsh P, Tiffin PA. Experience of Child and Adolescent Mental Health Clinicians working within an at-risk mental state for psychosis service: a qualitative study. Early Interv Psychiatry 2012; 6: 207-211.
22. Yung AR, Yuen HP, McGorry PD etal. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005; 39: 964-971.
23. IBM Corp. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp, 2010.
24. Becker CB, Darius E, Schaumberg K. An analog study of patient preferences for exposure versus alternative treatments for posttraumatic stress disorder. Behav Res Ther 2007; 45: 2861-2873.
25. Mairs H, Lovell K, Campbell M, Keeley P. Development and pilot investigation of behavioral activation for negative symptoms. Behav Modif 2011; 35: 486-506.
26. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. doi: 10.1093/schbul/sbs136.
27. Amminger GP, Schäfer MR, Papageorgiou K etal. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.
28. Australian and New Zealand Clinical Trials Registry. The NEURAPRO-E Study: A multicenter Randomized Controlled Trial (RCT) of Omega-3 Fatty Acids and Cognitive-Behavioural Case Management for Symptomatic Patients at Ultra-High Risk for Early Progression to Schizophrenia and Other Psychotic Disorders to Assess the 6-month Transition Rate to First Episode Psychosis. 2008. [Cited 10 Jun 2013.] Available from URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83121